BioSpace News Archive

Bellerophon Therapeutics, Inc. announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

Albireo Pharma, Inc., a rare pediatric liver disease company developing novel bile acid modulators, announced that it has entered into a definitive agreement to sell its Priority Review Voucher for $105 million.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect to its resubmission timeline for the DefenCath New Drug Application (“NDA”).

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer.

Locanabio, Inc. today announced the appointment of Kat Lange as chief financial officer.

Isoprene Pharmaceuticals, Inc., an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer (TNBC) and other cancers, today announced that the National Institute of Health’s (NIH) NCI has awarded the company a two-year $2 million Small Business Innovation Research (SBIR) Direct-to-Phase II grant.

Pear Therapeutics, Inc. today announced management’s participation in the Morgan Stanley 19th Annual Global Healthcare Conference.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021.

Panbela Therapeutics, Inc. today announced that it will present at upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

As recently presented in a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) held in June, radiopharmaceutical therapies clearly demonstrate an enormous potential in the battle against cancer.